Skip Navigation

Visiting Dana-Farber? See our prescreening and mask requirements.

Jia Luo, MD

Medical Oncology

Make an Appointment
Watch Video

Jia Luo, MD


  • Physician
  • Instructor in Medicine, Harvard Medical School


Clinical Interests

  • Cell-free DNA
  • Immunotherapy
  • Lung cancer
  • Lung cancer biomarkers
  • Targeted therapies

Contact Information

  • Appointments617-632-3468
  • Office Phone Number617-632-3468
  • Fax617-632-5786


Dr. Luo is a medical oncologist who specializes in care of people with lung cancer. Her approach to clinical care and research is informed by her unique background - learning laboratory research, programming, and clinical research skills during her training at institutions across the country. Dr. Luo strives to provide personalized compassionate care for patients and their families. Her research focuses on developing better treatments and treatment strategies by studying the genetic and immune characteristics of lung cancers. She also leads and develops clinical trials testing anticancer medicines that target cancers driven by these changes. Dr. Luo works with colleagues spanning the specialties involved in the care of people with lung cancer to develop the best treatment plans to increase the chance of cure. 

Board Certification:

  • Internal Medicine, 2017


  • Memorial Sloan Kettering Cancer Center, Medical Oncology


  • Oregon Health & Science University, Chief Resident in Internal Medicine
  • Oregon Health & Science University, Internal Medicine

Medical School:

  • Stanford University School of Medicine

Recent Awards:

  • Merit Award, American Society of Clinical Oncology (ASCO), 2021
  • Young Investigator Award (YIA), ASCO, 2020
  • Merit Award, ASCO, 2020
  • T32 Investigational Cancer Therapeutics Training Grant, 2019


Dr Luo's research is focused on deciphering the genetic and immune characteristics of lung cancers to understand why some people benefit from anticancer medicines for a limited time while others have long term benefit lasting years. She aims to develop better tools to identify those who benefit from treatment and design clinical trials of new targeted therapies and immunotherapies to increase the chance of cure.

She has first and co-authored papers in journals such as Cancer Discovery, Annals of Oncology, Nature Reviews Clinical Oncology, Cell Reports and Clinical Cancer Research. She has received grant support from foundations and the NIH.

ASCO Proceedings. Clinical and molecular features of long-term response to anti-PD-(L) 1 therapy in patients with advanced non-small cell lung cancer. 2023.

ASCO Proceedings. Initial chemotherapy for locally advanced and metastatic NUT carcinoma: A report from the NUT carcinoma registry. 2023.

Impact of Aneuploidy and Chromosome 9p Loss on Tumor Immune Microenvironment and Immune Checkpoint Inhibitor Efficacy in NSCLC. J Thorac Oncol. 2023 May 27.
View in: PubMed

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. Ann Oncol. 2023 Jul; 34(7):589-604.
View in: PubMed

Thoracic Malignancies. Pocket oncology. Third edition / edited by Drilon, A. Vasan, N, Choudhury, N, Murciano-Goroff, YR. 2022.

Phase I trial of the TNF-a inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nat Commun. 2022 10 15; 13(1):6095.
View in: PubMed

Safety of image guided research biopsies in patients with thoracic malignancies. Lung Cancer. 2022 11; 173:53-57.
View in: PubMed

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. Nat Cancer. 2022 10; 3(10):1151-1164.
View in: PubMed

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer. Ann Oncol. 2022 10; 33(10):1029-1040.
View in: PubMed

Deciphering radiological stable disease to immune checkpoint inhibitors. Ann Oncol. 2022 08; 33(8):824-835.
View in: PubMed

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience. JTO Clin Res Rep. 2022 Jun; 3(6):100328.
View in: PubMed

Overcoming KRAS-Mutant Lung Cancer. Am Soc Clin Oncol Educ Book. 2022 Apr; 42:1-11.
View in: PubMed

Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. J Thorac Oncol. 2021 10; 16(10):1759-1764.
View in: PubMed

Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. Clin Cancer Res. 2021 09 15; 27(18):5131-5140.
View in: PubMed

Association of prior radiation dose to the cardiopulmonary system with COVID-19 outcomes in patients with cancer. Radiother Oncol. 2021 08; 161:115-117.
View in: PubMed

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021 02; 9(2).
View in: PubMed

Erlotinib and Trametinib in Patients With EGFR-Mutant Lung Adenocarcinoma and Acquired Resistance to a Prior Tyrosine Kinase Inhibitor. JCO Precis Oncol. 2021; 5.
View in: PubMed

Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade. Cancer Discov. 2021 01; 11(1):59-67.
View in: PubMed

Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade. Cancer Discov. 2020 12; 10(12):1842-1853.
View in: PubMed

Outcomes to first-line pembrolizumab in patients with PD-L1-high (=50%) non-small cell lung cancer and a poor performance status. J Immunother Cancer. 2020 08; 8(2).
View in: PubMed

COVID-19 in patients with lung cancer. Ann Oncol. 2020 10; 31(10):1386-1396.
View in: PubMed

MET-dependent solid tumours - molecular diagnosis and targeted therapy. Nat Rev Clin Oncol. 2020 09; 17(9):569-587.
View in: PubMed

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers. Cancer Discov. 2020 08; 10(8):1121-1128.
View in: PubMed

Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12.
View in: PubMed

Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. Clin Cancer Res. 2020 06 15; 26(12):2849-2858.
View in: PubMed

A systematic review of head-to-head trials of approved monoclonal antibodies used in cancer: an overview of the clinical trials agenda. J Cancer Res Clin Oncol. 2019 Sep; 145(9):2303-2311.
View in: PubMed

Management of Localized Breast Angiosarcoma by North American Radiation and Medical Oncologists. Clin Breast Cancer. 2018 12; 18(6):498-503.
View in: PubMed

A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer. 2018 09; 101:143-151.
View in: PubMed

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives. Res Rep Urol. 2016; 8:217-224.
View in: PubMed

Current Patterns of Care for Patients with Extensive-Stage SCLC: Survey of U.S. Radiation Oncologists on Their Recommendations Regarding Prophylactic Cranial Irradiation. J Thorac Oncol. 2016 08; 11(8):1305-1310.
View in: PubMed

AMP-Activated Protein Kinase Directly Phosphorylates and Destabilizes Hedgehog Pathway Transcription Factor GLI1 in Medulloblastoma. Cell Rep. 2015 Jul 28; 12(4):599-609.
View in: PubMed

Symptoms and palliative care needs of pancreatic adenocarcinoma patients. J Palliat Med. 2014 Jun; 17(6):640-1.
View in: PubMed


Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions